Gnant M et al. Adjuvant palbociclib in HR+/HER2- early breast cancer: Final results from 5,760 patients in the randomized phase III PALLAS trial. SABCS 2021;Abstract GS1-07.

Harbeck N et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: Updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol 2021;32(12):1571-81. Abstract

Hurvitz SA et al. Neoadjuvant giredestrant (GDC-9545) + palbociclib versus anastrozole + palbociclib in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer: Primary analysis of the randomized, open-label, phase II coopERA breast cancer study. SABCS 2021;Abstract PD13-06.

Kalinsky KM et al. Updated results from a phase 3 randomized clinical trial in participants (pts) with 1-3 positive lymph nodes (LN), hormone receptor-positive (HR+) and HER2-negative (HER2-) breast cancer (BC) with recurrence score (RS) < 25 randomized to endocrine therapy (ET) +/- chemotherapy (CT): SWOG S1007 (RxPONDER). SABCS 2021;Abstract GS2-07.

Loibl S et al. Palbociclib for residual high-risk invasive HR-positive and HER2-negative early breast cancer: The PENELOPE-B trial. J Clin Oncol 2021;39(14):1518-30. Abstract

Mayer EL et al. Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): Interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2021;22(2):212-22. Abstract

O’Shaughnessy J et al. Adjuvant abemaciclib combined with endocrine therapy (ET): Updated results from monarchE. ESMO 2021;Abstract VP8-2021.

Pagani O et al. Absolute improvements in freedom from distant recurrence to tailor adjuvant endocrine therapies for premenopausal women: Results from TEXT and SOFT. J Clin Oncol 2020;38(12):1293-303. Abstract

Safonov A et al. Comprehensive genomic profiling of patients with breast cancer identifies germline-somatic interactions mediating therapy resistance. SABCS 2021;Abstract GS4-08.